The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application.

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the company’s share price on Tuesday.